文献速递乳腺癌

吡咯替尼对比拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌的随机II期研究

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
PubMed 文献 · J Clin Oncol · 2019-08-20

该随机II期研究纳入128例既往接受过紫杉类、蒽环类和/或曲妥珠单抗治疗的HER2阳性转移性乳腺癌中国患者,1:1随机接受吡咯替尼或拉帕替尼联合卡培他滨治疗。

要点

  • 吡咯替尼联合卡培他滨较拉帕替尼联合卡培他滨显著提高客观缓解率(78.5% vs 57.1%)。
  • 吡咯替尼组中位无进展生存期显著延长(18.1个月 vs 7.0个月,HR=0.36)。
  • 吡咯替尼组3-4级腹泻发生率较高(15.4% vs 4.8%),需注意管理。

核心结论

  • 在既往接受过紫杉类、蒽环类和/或曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者中,吡咯替尼联合卡培他滨的客观缓解率和无进展生存期均显著优于拉帕替尼联合卡培他滨。

研究设计与样本

  • 开放标签、多中心、随机II期研究,纳入128例中国HER2阳性复发或转移性乳腺癌患者,1:1随机分配至吡咯替尼组(n=65)或拉帕替尼组(n=63)。
  • 吡咯替尼400 mg或拉帕替尼1250 mg口服每日一次,联合卡培他滨1000 mg/m²口服每日两次(第1-14天),21天为一周期。
  • 主要终点为研究者根据RECIST 1.1评估的客观缓解率。

主要发现

  • 最常见的3-4级不良事件:手足综合征吡咯替尼组16/65例(24.6%) vs 拉帕替尼组13/63例(20.6%);腹泻分别为10例(15.4%) vs 3例(4.8%);中性粒细胞计数下降分别为6例(9.2%) vs 2例(3.2%)。

临床怎么用

  • 对于既往接受过紫杉类、蒽环类和/或曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者,吡咯替尼联合卡培他滨可作为治疗选择。
  • 治疗期间需密切监测腹泻等不良反应,尤其是吡咯替尼组3-4级腹泻发生率较高。

局限性

  • 本研究为II期研究,样本量有限(128例),结论需III期试验进一步验证。
  • 研究人群仅为中国患者,结果外推需谨慎。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study. PATIENTS AND METHODS: Chinese patients with HER2-positive relapsed or metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400 mg pyrotinib or lapatinib 1,250 mg orally once per day for 21-day cycles in combination with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14). The primary end point was investigator-assessed overall response rate per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS: Between May 29, 2015, and March 15, 2016, 128 eligible patients were randomly assigned to the pyrotinib (n = 65) or lapatinib (n = 63) treatment groups. The overall response rate was 78.5% (95% CI, 68.5% to 88.5%) with pyrotinib and 57.1% (95% CI, 44.9% to 69.4%) with lapatinib (treatment difference, 21.3%; 95% CI, 4.0% to 38.7%; P = .01). The median progression-free survival was 18.1 months (95% CI, 13.9 months to not reached) with pyrotinib and 7.0 months (95% CI, 5.6 to 9.8 months) with lapatinib (adjusted hazard ratio, 0.36; 95% CI, 0.23 to 0.58; P < .001). The most frequent grade 3 to 4 adverse events were hand-foot syndrome in 16 of 65 patients (24.6%) in the pyrotinib group versus 13 of 63 (20.6%) in the lapatinib group; diarrhea in 10 patients (15.4%) versus three patients (4.8%), respectively; and decreased neutrophil count in six patients (9.2%) versus two patients (3.2%), respectively. CONCLUSION: In women with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines, and/or trastuzumab, pyrotinib plus capecitabine yielded statistically significant better overall response rate and progression-free survival than lapatinib plus capecitabine in this randomized phase II trial.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ma F, Ouyang Q, Li W, et al. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. J Clin Oncol. 2019. PMID: 31430226. doi:10.1200/JCO.19.00108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。